Cristian Massacesi: Very much enjoyed being part of the Endpoints panel at ASCO2024

Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, posted on LinkedIn:

“Very much enjoyed being part of the Endpoints panel at ASCO2024. Alongside Julie Gralow, Timothy A. Yap and Kyle LaHucik, we reviewed the major scientific breakthroughs from this year’s conference and how these advances could potentially translate into improved outcomes for patients.

Themes from the discussion close to my heart included:

• How the deeper convergence of science, data and technology can support smarter and faster decision-making in discovery and development.
• How to further enhance precision medicine and better, targeted treatments in oncology, with great focus on how to improve and manage toxicities.
• Exciting progress with new, disruptive modalities and the opportunities for combinations to offer even more transformational cancer regimens.
• The growth in antibody drug conjugates and how they can be best sequenced across different disease settings for maximum impact.

Another excellent ASCO on many levels. There’s certainly never been a more exciting time to be working in oncology.”

Source: Cristian Massacesi/LinkedIn
.